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A cute kidney injury (AKI) occurs in 7% to 18% ofhospitalized patients and complicates the course of
50% to 60% of those admitted to the intensive care unit,
carrying both signiﬁcant mortality and morbidity.1 Even
though many cases of AKI are reversible within days to
weeks of occurrence, data from multiple large observational
and epidemiological studies over the past decade suggest a
strong association between AKI and subsequent chronic
kidney disease (CKD) and end-stage renal disease (ESRD).2,3
Patients with AKI who receive renal replacement therapy
(RRT) are >3 times more likely to develop ESRD than those
who do not. This rise in the number of patients who receive
treatment for ESRD is a global phenomenon associated with
considerable patient costs, effects on quality of life, and
economic impact on society as a whole. In developing
countries, most people with kidney failure have insufﬁcient
access to dialysis and/or kidney transplantation. Conse-
quently, the development of effective approaches to the
prevention, early recognition, and management of AKI is
necessary to reduce the burden of CKD and ESRD.4
Millions of patients undergo cardiac and vascular surgery
(CVS) every year in developed countries alone. AKI is a
From the Division of Nephrology & Hypertension, Department of Medicine (M.K.N.) and Division of Vascular Surgery, Department of Surgery (F.A.W.), Keck School of
Medicine, University of Southern California, Los Angeles, CA; Department of Clinical & Experimental Medicine, University of Surrey, Guildford, United Kingdom (L.G.F.);
Royal Surrey County Hospital NHS Foundation Trust, Guildford, United Kingdom (L.G.F.); Division of Nephrology, Hypertension & Renal Transplantation, Department of
Medicine, University of Florida, Gainesville, FL (A.B.); Division of Surgical Critical Care, Department of Surgery, Malcom Randall VA Medical Center, Gainesville, FL
(C.H.); Section of Nephrology, Department of Medicine, University of Chicago, IL (J.L.K.); Department of Anesthesiology, Vanderbilt University Medical Center, Nashville,
TN (A.S.); Division of Thoracic & Cardiovascular Surgery, Department of Surgery, University of Florida College of Medicine, Gainesville, FL (G.J.A.); Department of
Nephrology, Shanghai Institute for Kidney Disease and Dialysis, Shanghai Medical Center for Kidney Disease, Zhongshan Hospital, Fudan University, Shanghai, China
(X.D.); Division of Cardiac Surgery, Department of Surgery, Baystate Medical Center, University of Massachusetts Medical School, Springﬁeld, MA (D.T.E.); Department
of Cardiac Surgery, University Hospital Rebro, Zagreb, Croatia (H.G.); Department of Medicine, University of Zagreb, Croatia (V.G.); Division of Cardiology, Department
of Medicine, Hennepin County Medical Center, University of Minnesota, Minneapolis, MN (C.A.H.); Division of Nephrology & Hypertension, Division of Pulmonary and
Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, MN (K.K.); Division of Cardiac Surgery, Department of Surgery, Johns Hopkins University,
Baltimore, MD (N.K.); Divisions of Nephrology and Critical Care, Departments of Medicine and Anesthesia, University of California, San Francisco, CA (K.D.L.);
Department of Medicine, UCSD Medical Center, University of California, San Diego, CA (R.L.M.); King’s College London, Guy’s & St Thomas’ Hospital, London, United
Kingdom (M.O.); Division of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada (N.P.); Department Intensive Care
Medicine, Radboud University Medical Center, Nijmegen, The Netherlands (P.P.); Adult Intensive Care Unit, Imperial College, Royal Brompton Hospital, London, United
Kingdom (S.P.); Department of Pediatric Cardiac Surgery, Bambino Gesu Children’s Hospital, Roma, Italy (Z.R.); Heart and Vascular Institute, Cleveland Clinic, Cleveland,
OH (J.B.R.); Division of Cardiothoracic Surgery, STAR Hospitals, Hyderabad, India (L.R.S.); Department of Anesthesiology, Intensive Care and Pain Medicine, University
Hospital M€unster, M€unster, Germany (A.Z.); Department of Nephrology, Dialysis and Transplantation, San Bortolo Hospital, International Renal Research Institute of
Vicenza, Italy (C.R.); Department of Critical Care Medicine, School of Medicine, University of Pittsburgh, PA (J.A.K.).
Accompanying Table S1 and Data S1 are available at http://jaha.ahajournals.org/content/7/11/e008834/DC1/embed/inline-supplementary-material-1.pdf
Correspondence to: Mitra K. Nadim, MD, FASN, Division of Nephrology & Hypertension, Department of Medicine, Keck School of Medicine, University of Southern
California, 1520 San Pablo St., Suite 4300, Los Angeles, CA 90033. E-mail: nadim@usc.edu
J Am Heart Assoc. 2018;7:e008834. DOI: 10.1161/JAHA.118.008834.
Received March 16, 2018; accepted March 23, 2018.
ª 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons
Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
DOI: 10.1161/JAHA.118.008834 Journal of the American Heart Association 1
SPECIAL REPORT
D
ow
nloaded from
 http://ahajournals.org by on October 25, 2019
common perioperative complication for patients undergoing
both cardiac surgery5–9 and vascular surgery,9–11 occurring in
20% to 70% of cases depending on the type of surgery and the
deﬁnition of AKI used. In addition, more and more of these
patients who receive complex CVS are elderly with multiple
comorbidities, which predispose to the development of AKI
and potentially hasten progression to ESRD. Mortality rates
among cardiovascular patients undergoing RRT are between
40% and 70%, and mortality is associated with both the
severity of the initial insult and the number of episodes of AKI
occurring during the hospital admission.12,13
In recent years, there have been considerable advances in
our understanding of CVS-associated AKI (CVS-AKI). Never-
theless, despite the high prevalence, there is little consensus
about how best to prevent or treat CVS-AKI. The aim of this
consensus process was to review the current literature on
CVS-AKI; to create the basis for its deﬁnition; to develop an
initial understanding of its pathophysiology; to explore the
potential use of biomarkers for its diagnosis; to critique
current literature in the ﬁelds of prevention and treatment, so
as to make recommendations for clinical practice; and to
propose a framework for future research.
Methods
ADQI (Acute Disease Quality Initiative) is an ongoing process
that produces evidence-based recommendations on the
diagnosis, prevention, and management of AKI and on various
issues concerning acute dialysis and ﬂuid management
(http://www.adqi.org). The conference chairs of the 20th
ADQI consensus committee (M.K.N., J.A.K., V.G., C.R., and
L.G.F.) convened a panel of experts representing the relevant
disciplines—cardiac surgery, vascular surgery, cardiology,
nephrology, anesthesiology, and critical care—from North
America, Europe, and Asia to discuss the issues related to
CVS-AKI (Data S1). The conference took place June 16 to 19,
2017, and the format of the meeting was a 2.5-day modiﬁed
Delphi method to achieve consensus, as described previously
(Data S1).14
Results and Discussion
Pathophysiology
The pathophysiology of CVS-AKI is complex and poorly
understood. Although patients undergoing cardiac and major
vascular surgery may experience similar insults to the
kidneys, many distinctions exist between these populations.
Notable differences are the relative inﬂuence of cardiac
dysfunction (greater in cardiac surgery) versus warm
ischemia–reperfusion injury to the kidneys and increased
abdominal pressures (both greater with vascular surgery).
Finally, the effect of the cardiopulmonary bypass (CPB) circuit
itself in the case of cardiac surgery is notable. Although
animal models15,16 of CPB and cardiac surgery–associated
AKI (CS-AKI) exist, they have not been widely applied to the
study of AKI. Furthermore, although clinical studies have been
conducted for >40 years, numerous knowledge gaps remain.
Observational studies, animal and cell culture work, and
mathematical simulations17 are currently available to predict
the events likely to occur during cardiac surgery. Hemody-
namic disturbances at each level of arterial blood supply
dominate the discussion, and inﬂammatory, immunological,
neurohumoral, and mechanical factors are also of signiﬁcance
(Figure 1).
Hemodynamic perturbations
Perturbations in the renal blood ﬂow may lead to an
imbalance of oxygen supply and demand.18,19 The inner
stripe of the outer medullary portion of the kidney may be
susceptible to ischemic damage caused by low resting PO2
(10–20 mm Hg).18 During CPB, cardiac output is preserved,
but the target blood pressure under such nonpulsatile
conditions is unknown, and inadequate renal perfusion may
contribute to AKI. However, using a mathematical model,17
the rewarming phase of CPB appeared to represent the period
when the renal medulla may be at most risk because of the
combination of high oxygen demand and low oxygen supply
occurring at this time. Low cardiac output states during and
after cardiac surgery are likely to contribute to the ischemic
process, although whether low ﬂow, low blood pressure, or
oxygen delivery is the main culprit remains elusive.20 Studies
of noncardiac surgery patients suggest that maintenance of
sufﬁcient mean arterial pressure is the most important
hemodynamic parameter to preserve in the perioperative
period21,22; however, these patients are rarely exposed to
hypothermia and hemodilution, so it remains unclear whether
this ﬁnding also applies to cardiac surgery patients.
The period after CPB may be relevant for the development
of reperfusion injury,23 and the precise underlying mecha-
nisms need to be fully understood so that preventive and
salvage treatments may be developed to mitigate this
process. Remote ischemic preconditioning (RIPC) appeared
to show great promise in a study of high-risk patients24 but
has been shown to be ineffective (at least with respect to the
effect sizes examined) in lower risk patients.25–27 Some
controversy exists regarding the effects of propofol, which has
been hypothesized to attenuate the response to RIPC.26
The role of venous congestion in the development of AKI is
a potential area of pathophysiological signiﬁcance.28,29 The
role of high central venous pressure in congestive heart failure
is well appreciated.30 The incidence of AKI in this population
has led investigators to study it in the context of heart
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surgery, for which the problem is typically in the right heart,
and vascular surgery, for which the problem may be increased
abdominal compartment pressures. However, the mecha-
nisms involved are unclear, and although “back pressure” on
the glomerular apparatus has been postulated, it is unlikely
that this process is the sole cause of this observation. It may
be that the renal pelvis is able to compensate for a certain
amount of increased venous volume before the pressure–ﬂow
relationship inside the poorly compliant renal capsule
changes, in keeping with the Monro–Kellie doctrine observed
in the brain.31 Whether this truly applies to the kidney is
currently a matter of speculation but one that merits further
study.
Inﬂammation and immunity
The systemic inﬂammatory response is often observed
following major surgery, with considerable variability observed
between individuals, although it is recognized that a more
severe response is associated with an increased risk of
adverse outcomes including AKI.32–34 Unsurprisingly, CVS is
often associated with such a response and may activate the
inﬂammatory cascade through several pathways.35,36 CVS
exposes the patient to a risk proﬁle somewhat different from
most other major surgeries. CPB, cross-clamping of the aorta,
high doses of exogenous vasopressors, and high rates of
exogenous blood product transfusion, for example, all
enhance the risks of AKI, especially when coupled with the
risk proﬁle for AKI for most of these patients. Such exposures
are associated with perturbations in renal perfusion that
induce reperfusion injury following episodes of ischemia,
resulting in increased oxidative stress and associated
inﬂammation.37,38 This process is exacerbated by the signif-
icant shunting within the kidney that results in the renal
medulla and corticomedullary junction being relatively hypoxic
relative to other tissues.18 In cardiac surgery, the entire
cardiac output is exposed to an extracorporeal circuit, and
this provides a further inﬂammatory insult through contact
activation from the exposure of blood to the CPB circuit;
although in the modern CPB circuit biocompatibility has been
optimized, measures of immune activation (cytokine and
chemokine levels) increase signiﬁcantly after CPB.36 The
generation of reactive oxygen species induces inﬂammation
by upregulation of proinﬂammatory transcription factors,
including NFj-B (nuclear factor j-B).39,40 Cytokines and
chemokines recruit neutrophils, macrophages, and lympho-
cytes into the renal parenchyma. Parenchymal inﬁltration and
activation of these immune cells promote AKI and lead to
ﬁbrosis. Avoidance of the CPB machine in an attempt to
reduce distant organ function has been successful,41 although
recently published data suggest that 5-year survival is lower
with off-pump techniques42; this may be a reﬂection of
improved revascularization of the heart with the on-pump
technique. In the presence of concurrent sepsis, such as with
bacterial endocarditis, sepsis and surgery appear to be
synergistic in terms of affecting an immune response.43
Iron metabolism and free hemoglobin
CVS leads to free hemoglobin liberation with the release of
free iron, and this phenomenon has generated much interest
regarding CS-AKI.44–47 A degree of hemolysis is inevitable
whenever red blood cells come into contact with an artiﬁcial
surface or with air (eg, blood scavenging systems), and this
may be coupled with a prolonged period of hypothermia
(sometimes as low as 18°C), which creates the perfect
environment for hemolysis and liberation of free iron, leading
to vasoconstriction through scavenging of nitric oxide by free
hemoglobin. Indeed, evidence from a case–control study of
patients who developed AKI postoperatively compared with
matched controls demonstrated that plasma-free hemoglobin
was less than half that observed in the control group, providing
further evidence that hemolysis and free iron may contribute
to AKI development.44 Moreover, free hemoglobin and,
particularly, free ferrous iron increase production of reactive
oxygen species via the Fenton and Haber Weis reactions,
especially as free hemoglobin and iron are sequestered within
the kidney.48 Plasma-free hemoglobin also induces HO-1
(heme oxygenase 1) expression. HO-1 degrades heme but
increases in experimental models of AKI. Plasma HO-1 is
increased in patients who develop AKI, and CPB duration,
hemolysis, and inﬂammation are associated with increased
HO-1 concentrations following cardiac surgery.45
Other mechanisms
Oxygen free radical generation and metabolism is an area of
active investigation49,50 (and genetic predisposition to injury
is important51,52), but it is not clear whether this results in
increased susceptibility to AKI or to innate impairment of the
ability to repair and regenerate healthy renal tissue. The
precise nature of the genetic (and epigenetic) variables
involved also remains unclear. Furthermore, embolic disease
is important for CS-AKI. Cholesterol emboli53 are at risk for
distal migration when a cross-clamp is applied or released
from the aorta, especially in patients with signiﬁcant
atherosclerosis. Moreover, intra-aortic balloon counterpulsa-
tion devices increase the embolic load, and the fact that these
devices are typically deployed in patients with severely
compromised hemodynamic conditions makes it difﬁcult to
discern whether such devices are of overall beneﬁt (by
improving cardiac output) or harm (by increasing generation
of emboli) to the kidney. In addition, tissue injury releases
mitochondrial damage–associated molecular patterns includ-
ing mitochondrial DNA, which can act as a direct activator of
neutrophils, which in turn elicit a systemic inﬂammatory
response syndrome while suppressing polymorphonuclear
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function. Such molecular patterns have also been seen during
CPB and, as such, may participate in the pathogenesis of CVS-
AKI.54
Diagnosis and Risk Assessment
Perioperative stratiﬁcation for AKI
Recommendation:
We recommend routine implementation of validated clin-
ical risk-prediction models in the preoperative assessment
of all patients undergoing CVS, using estimated glomerular
ﬁltration rate (eGFR), cystatin C, and/or albuminuria to
improve risk stratiﬁcation of those at intermediate and
high risk of AKI postoperatively (not graded).
Rationale: Risk assessment is a dynamic process in which
patients with ﬁxed preoperative risk derived from underlying
comorbidities are evaluated on the basis of additional and
potentially modiﬁable risks from their clinical status before
surgery. The use of currently available risk-prediction instru-
ments must be guided by the goals of risk assessment in each
instance. Preoperative risk assessment may be useful for
communicating risks associated with surgery to the patient
and in implementing preventive strategies in the intra- and
postoperative periods, for example, goal-directed hemo-
dynamic management, individualized blood pressure
management,21 and avoidance of the use of NSAIDs for pain
management. Postoperative risk assessment is geared toward
early identiﬁcation of AKI that may allow earlier
Figure 1. Major pathophysiological mechanisms for the development of cardiac and vascular surgery–
associated acute kidney injury (CVS-AKI). Many common factors contribute to the development of CVS-
AKI. Hemodynamic perturbations such as exposure to cardiopulmonary bypass (CPB), cross-clamping of
the aorta, high doses of exogenous vasopressors, and blood-product transfusion all increase the risk of
AKI. Similarly, the mechanical factors outlined may be associated with renal perfusion injury following
episodes of ischemia, resulting in increased oxidative stress and associated inﬂammation as well as
embolic disease including cholesterol emboli, all of which increase the pathological burden on the kidney.
Other mechanisms such as neurohormonal activation are relevant, as is the generation of free hemoglobin
and the liberation of free iron perioperatively, all potentiating AKI. Associated tissue damage is reﬂected in
a systemic inﬂammatory response, and all these factors contribute to a signiﬁcant inﬂammatory response.
Immune activation, the generation of reactive oxygen species, and upregulation of proinﬂammatory
transcription factors all play roles.
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implementation of preventive strategies. Peri- and postoper-
ative risk assessment is geared toward early identiﬁcation of
AKI that may allow proactive treatment. An important
conceptual point is that kidney injury in the setting of CVS
occurs along a continuum and may relate to patient,
preoperative, and intraoperative factors and the trajectory
of AKI occurrence from baseline conditions; its development
over a patient’s clinical course should take this aspect into
account (Figure 2).
Although many risk-prediction scores for AKI after cardiac
surgery have been published, only 8 have been externally
validated with C statistics ranging from 0.72 to 0.89
(Table S1).55–61 In general, these scoring systems have good
discrimination in assessing low-risk groups but relatively poor
discrimination in moderate to high-risk patients.62 There are
no externally validated risk-assessment tools speciﬁcally for
AKI following vascular surgery; although Kheterpal and
colleagues developed and externally validated an AKI risk
score for general surgery cases that included but was not
limited to vascular surgery.63,64 The most robust cardiac
surgery prediction tools with the best discrimination have
used AKI requiring RRT as an outcome. This is problematic
because AKI requiring dialysis, although catastrophic in this
context, is relatively uncommon, occurring in 1% to 2% of all
patients undergoing surgery in most programs. In addition,
the decision to initiate RRT varies among clinicians. Less
severe forms of AKI are commonly seen after cardiac surgery
with reported rates of Kidney Disease Improving Global
Outcomes (KDIGO) stage 1 AKI reported between 20% and
70% depending on the patient risk factors and the inclusion of
KDIGO serum creatinine (sCr) and/or urine output (UO)
criteria for AKI.7,8,65–68 Three of the prediction rules have
assessed risk of less severe forms of AKI deﬁned using sCr
criteria only.56,58,69 Of these, one used the RIFLE criteria of
AKI,56 and another used the Acute Kidney Injury Network
criteria.69
The risk factors commonly identiﬁed in externally validated
risk-prediction models are shown in Figure 2. Preexisting
CKD, although variably deﬁned, is the strongest risk factor for
AKI in this setting. With 2 exceptions,59,70 most other
prediction tools have used sCr to assess kidney function,
which may signiﬁcantly overestimate kidney function, partic-
ularly in malnourished elderly populations. The eGFR, which
accounts for age, race, and sex and is subject to similar
limitations, is likely a more accurate estimation of kidney
function in stable, elective patients. The use of both eGFR and
sCr in this context assumes steady-state kidney function,
which is frequently not the case. Newly identiﬁed risk factors
such as preoperative hemoglobin (anemia/transfusion load)
and proteinuria have only been incorporated in recent models,
whereas other risk factors have not been rigorously studied
for their incremental value when added to existing risk-
prediction models (eg, days from cardiac catheterization to
surgery). All risk-prediction tools have shown only moderate
calibration, suggesting signiﬁcant heterogeneity in the under-
lying populations.62 Because most risk-prediction tools have
been derived from clinical and administrative databases, they
fail to capture acuity of illness, which may account for the
calibration discrepancies and the difﬁculty in discrimination
among the moderate- to high-risk groups. Some measure or
surrogate for hemodynamic stability is present in all published
models whether it is characterized by surgical urgency or the
presence of cardiogenic shock. It is likely that risk discrim-
ination would improve if additional objectively deﬁned clinical
variables were included.
At a minimum, all patients undergoing cardiac and vascular
surgical procedures should undergo routine clinical assess-
ment of AKI risk. This involves systematic evaluation of known
susceptibilities for development of AKI such as CKD and
albuminuria using preoperative sCr and urinalysis in all
patients before surgery.71–73 These results will help frame
individualized risk for AKI while perhaps providing insight into
patients’ baseline renal function. Whenever possible, efforts
should be made to obtain the patient’s prior kidney-function
tests to ascertain true baseline function. In summary, the
currently available preoperative risk-assessment tools are
beneﬁcial in that they use commonly available data and
identify low-risk patients in the setting of traditional CVS.
Nevertheless, they have several limitations:
1. They are predominantly used to predict RRT.
2. Sensitivity and speciﬁcity break down at the extremes of
the spectrum.
3. They do not account for preoperative eGFR (primarily rely
on sCr alone).
Intra- and postoperative factors play equally important roles in
determining the course and severity of AKI; as such,
continued risk assessment throughout the peri- and postop-
erative periods is crucial for patients at risk of AKI.
Deﬁnition and diagnosis of AKI
Recommendations:
1. We recommend that AKI should be deﬁned by the KDIGO
criteria, including both sCr and UO criteria (not graded).
2. We recommend checking sCr immediately before surgery
in all patients and utilizing sCr-based eGFR to assess renal
function in patients with steady state preoperatively so as
to ascertain AKI postoperatively (not graded).
3. We recommend repeated clinical reassessment of AKI risk
within the ﬁrst 12 postoperative hours incorporating intra-
and postoperative variables (not graded).
4. We suggest measuring biomarkers of AKI (eg,
TIMP2IGFBP7 [combination of tissue inhibitor of metallo-
proteinases 2 and insulin-like growth factor binding protein
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7] or NGAL [neutrophil gelatinase–associated lipocalin]) in
patients at high risk of CS-AKI (grade 2A).
Rationale: The current Society of Thoracic Surgeons (STS)
database deﬁnes AKI by KDIGO sCr-based stage 3 AKI (sCr ≥3
times baseline or initiation of RRT).74 However, smaller
changes in sCr are associated with adverse outcomes
following CVS.75–78 Given the association of stage 1 AKI
(sCr 1.5 times baseline or ≥0.3-mg/dL increase within
48 hours) with adverse outcomes in multiple settings, it is
important to recognize stage 1 AKI (based on sCr and/or UO
criteria) so that the progression to stage 2 (sCr 2.0 times
baseline) or stage 3 AKI and other outcomes can be
monitored. In addition, sCr criteria alone may miss 30% of
patients with AKI, resulting in both misclassiﬁcation of AKI
severity and delay in management. Critically ill patients who
meet AKI criteria by both sCr and UO are at higher risk of
adverse outcomes including 30-day mortality and need for
RRT in comparison to those who meet a single criterion for
AKI.5,79–81 The STS database does not distinguish between
AKI and acute kidney disease, which is currently deﬁned as
the course of the AKI syndrome in those who continue to have
renal pathophysiological changes 7 days after the inciting
event. Acute kidney disease may last for weeks to months
with variable outcomes (full or partial recovery, ESRD).82
Moreover, the timing and trajectory of AKI (<7 days versus 7–
30 days) after CVS can provide insight into the cause of
kidney dysfunction and may likely have different associations
with adverse outcomes.
We recommend checking sCr in all patients to determine
preoperative baseline kidney function. The time frame
depends on the presence of acute illness and other factors
that may affect kidney health (eg, recent exposure to
iodinated contrast in the setting of cardiac catheterization,
medications including angiotensin-converting enzyme inhibi-
tors and angiotensin receptor blockers). In the absence of
such factors, it is reasonable to obtain preoperative baseline
sCr within 2 weeks of surgery. When sCr is at steady state
(eg, stable for 48 hours), it can be used to calculate eGFR
Figure 2. Risk assessment for acute kidney injury (AKI) following cardiac and vascular surgery (CVS).
This ﬁgure provides a framework for the time course of risk assessment for AKI following CVS. Risk
assessment should be a continual process that is repeatedly performed in the pre-, peri-, and early
postoperative time course, and it should incorporate clinical factors and biomarkers if available. Patients
deemed to be at high risk of AKI may beneﬁt from the implementation of kidney-focused care to improve
patient outcomes. CHF indicates congestive heart failure; COPD, chronic obstructive pulmonary disease;
CPB, cardiopulmonary bypass; EF, ejection fraction; IABP, intra-aortic balloon pump; IGFBP7, insulin-like
growth factor binding protein 7; KDIGO, Kidney Disease Initiative Global Outcome; NGAL, neutrophil
gelatinase–associated lipocalin; PVD, peripheral vascular disease; TIMP2, tissue inhibitor of metallopro-
teinases 2.
DOI: 10.1161/JAHA.118.008834 Journal of the American Heart Association 6
Cardiac and Vascular Surgery–Associated AKI Nadim et al
S
P
E
C
IA
L
R
E
P
O
R
T
D
ow
nloaded from
 http://ahajournals.org by on October 25, 2019
using validated estimating equations (eg, Chronic Kidney
Disease–Epidemiology Collaboration [CKD-EPI] or Modiﬁca-
tion of Diet in Renal Disease [MDRD]) to assess for CKD.83 For
urgent or emergent surgical procedures, when sCr is less
likely to be in steady state, the preoperative baseline sCr
should be obtained within 24 hours of surgery and, ideally, as
close as possible to the start of surgery. In these cases,
clinical factors that contribute to the urgency of surgery (eg,
cardiogenic shock) are likely to affect sCr and kidney function
adversely.
Pitfalls of AKI deﬁnitions. Several speciﬁc challenges for
AKI deﬁnitions exist in the context of cardiac surgery. In the
setting of CPB, hemodilution frequently results in postoper-
ative sCr below the preoperative baseline. Given the limita-
tions of sCr, certain subpopulations may be particularly prone
to overestimation of baseline kidney function, including
elderly patients, sarcopenic patients, or those with signiﬁcant
volume overload. Given the importance of underlying CKD as
a risk factor for perioperative AKI, this is most relevant for
preoperative risk assessment. In these patients, quantitation
of kidney function with cystatin C or timed creatinine
clearances or eGFR equations (eg, CKD-EPI or MDRD) may
be preferable approaches.83
Beyond sCr. Despite its ubiquitous use, sCr is an imperfect
marker for the early detection of AKI because rises in sCr are
delayed following the kidney insult. In patients with normal
preoperative renal function, GFR may decrease signiﬁcantly
with only minimal effect on sCr. During cardiac surgery, CPB
and intravenous ﬂuid administration may lead to hemodilution
of sCr in the perioperative period, delaying the recognition of
AKI. These limitations of sCr (and other functional biomarkers
of AKI such as UO) have led to a call for the use of tubular
damage and stress biomarkers for the recognition and
diagnosis of AKI.82 A recent consensus conference provided
a framework for the reclassiﬁcation of AKI along changes in
functional (sCr and UO) and damage or stress biomarkers
(Figure 3).84 Over the past decade, several biomarkers of AKI
have demonstrated the ability to detect kidney injury or stress
and have been proposed as tools to improve the evaluation
and treatment of patients with AKI.67,85–92
Importantly, damage may occur before reaching the AKI
threshold of changes in sCr or UO, reﬂecting delay in the
kinetics of these functional markers or the presence of renal
reserve (the compensatory ability of the kidney to increase
GFR in the face of increased demand). The best-studied and
most widely available biomarkers in the clinical setting are
urinary or plasma NGAL and TIMP2IGFBP7.67,85–93 NGAL has
been most successful in pediatric cardiac surgery, whereas
TIMP2IGFBP7 has been used in both adult and pediatric
cases. Thus, biomarkers may potentially reﬁne the clinical
management of AKI by providing both diagnostic and
prognostic information independent of the conventional
functional markers of AKI. Recent studies have demonstrated
that implementing kidney-focused care in the setting of
postoperative patients with elevated stress biomarkers leads
to improved patient outcomes (less AKI, less severe AKI, and
decreased length of stay).67,93 However, we recommend
applying the KDIGO bundle only to CVS patients who are at
high risk of AKI identiﬁed by biomarkers.
Prevention of CVS-AKI
Recommendations:
1. We recommend that a variety pharmacological and
nonpharmacological strategies be used to prevent AKI in
patients undergoing CVS (Table 1; grades 1A–2D).
2. We recommend avoiding certain interventions for preven-
tion of AKI that have been shown to be ineffective or to
cause harm (Table 1; grades 1A–1B).
3. A number of approaches to prevent AKI lack sufﬁcient
evidence for recommendation and are best avoided until
such evidence is available (Table 1; not graded).
4. We recommend avoiding hydroxyethyl starch (grade 1A)
and suggest judicious use of balanced crystalloid solutions
rather than saline or albumin solutions to replace ﬂuid
losses (grade 2B).
Rationale: The evidence for most pharmacological and
nonpharmacological strategies in the perioperative setting is
limited because the majority of studies are single center, are
of poor quality with small sample sizes, and/or use variable
inclusion criteria. In addition, the timing and dose of
pharmacological agents and the deﬁnition of AKI vary widely.
Pharmacological strategies
Perioperative. Numerous pharmacological agents including
levosimendan,94–97 statins,98–100 N-acetylcysteine,101–104
sodium bicarbonate,105–108 and erythropoietin109–113 have,
for the most part, failed to demonstrate beneﬁt for the
prevention of CS-AKI. A possible exception is dexmedeto-
midine, for which a number of small or low-quality studies
found a reduction in the occurrence of AKI after cardiac
surgery.114–116 Moderate glucose control (127–179 mg/dL)
was found in a randomized controlled trial (RCT) to be
preferable to tight control (≤126 mg/dL) in patients under-
going coronary artery bypass grafting,117 resulting in lower
rates of AKI and mortality, with the most important factor
being avoidance of glucose variability throughout the entire
perioperative time frame.118,119 The use of balanced crystal-
loid solutions guided by measures of ﬂuid responsiveness is
supported by the current literature and is consistent with the
recommendations for ﬂuid management in critically ill
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patients with sepsis.97,120–123 The administration of hydrox-
yethyl starch is not indicated for patients at risk of CS-AKI
because of its demonstrated renal toxicity.97,121 Although
albumin may have a role preoperatively in patients with
hypoalbuminemia,124 we suggest limiting colloid administra-
tion in cardiac surgery patients as much as possible and
recommend balanced crystalloid solutions as replacement
ﬂuid, in keeping with the literature.120
Preoperative. Although evidence is limited, several studies
demonstrate that withholding angiotensin-converting enzyme
inhibitors and angiotensin receptor blockers in the preoper-
ative period is associated with reduced incidence of AKI.125–
127 Correction of hypoalbuminemia (level of <4 g/dL) by
exogenous albumin supplementation has been shown to be
renoprotective in off-pump cardiac surgery.124,128
Intraoperative. Volatile anesthetics have been shown to
protect against AKI in clinical trials.129,130 A recently
published meta-analysis including 10 trials with 1600 total
participants demonstrated that volatile anesthetics signiﬁ-
cantly reduced AKI incidence compared with control data
(relative risk: 0.65; 95% conﬁdence interval, 0.43–0.97;
P=0.04). Although there was no signiﬁcant difference
between groups in absolute postoperative sCr level and
mortality, patients receiving volatile anesthetics had signiﬁ-
cantly (or borderline) lower increase in sCr level from baseline
on the ﬁrst and second postoperative days and reduced
incidence of prolonged intensive care unit stay and
hospitalization.131
Postoperative. For agents such as dopamine,132 a-
melanocyte–stimulating hormone analog,133 and loop
diuretics,134,135 evidence shows that their use in the preven-
tion of AKI either is not beneﬁcial or is potentially
harmful.132,134,135 Because the evidence for mannitol136–138
and fenoldopam139–143 is either weak or controversial, more
research is needed. Although natriuretic peptides have been
shown in some studies to reduce the incidence of AKI, the
need for RRT was similar, and the overall evidence for these
Figure 3. Classiﬁcation of acute kidney injury (AKI) by changes in function and/or damage. Currently
the diagnosis of AKI is made through changes in serum creatinine (sCr) or urine output (UO)—
functional biomarkers. The 10th Acute Disease Quality Initiative consensus meeting delineated criteria
for deﬁning AKI in terms of changes in biomarkers of renal function (sCr/UO) and biomarkers of kidney
damage. This paradigm allows for the combination of injury biomarkers with sCr and UO and has been
useful in the discrimination of patients with AKI. The terms prerenal and intrinsic AKI are sometimes
used to denote these relationships. The upper right box may be termed subclinical. The upper left box
is yellow because we may still miss changes in function and damage in some patients; a role for
additional diagnostics and/or stress tests is acknowledged.
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drugs was weak and controversial.144–152 Vasodilatory shock
(vasoplegia) has become a common occurrence, particularly
with the widespread use of angiotensin-converting enzyme
inhibitors and angiotensin receptor blockers.153 In a recent RCT
of patients with vasoplegic shock (deﬁned as mean arterial
pressure <65 mm Hg resistant to ﬂuid challenge and cardiac
Table 1. Strategies for Prevention of AKI After CVS
Timing Strategy Population Recommended Not Recommended
Perioperative Avoidance of glucose variability Cardiac 1B . . .
Balanced crystalloid (vs saline) Cardiac and vascular 1B . . .
Dexmedetomidine Cardiac 2C . . .
Statins Cardiac . . . 1A
N-acetylcysteine Cardiac . . . 1A
Sodium bicarbonate Cardiac . . . 1A
Levosimendan Cardiac . . . 1A
Limited use of blood transfusion Cardiac vascular 1A More research needed
Albumin (vs crystalloid) Cardiac . . . More research needed
Erythropoietin Cardiac and vascular . . . More research needed
Preoperative Discontinuation of ACEIs and ARBs Cardiac 1C . . .
Albumin in patients with hypoalbuminemia Cardiac (OPCAB) 2C . . .
24- to 72-h delay postcontrast before cardiac surgery Cardiac 2C . . .
IABP Cardiac 2C* . . .
Intraoperative Volatile anesthetic agents (vs propofol) Cardiac 2C . . .
Cold renal perfusion for AAA Vascular 2C . . .
Avoidance of hyperthermia Cardiac 2C . . .
Pulsatile CPB Cardiac 2D* . . .
Avoidance of hemodilution Cardiac 2C . . .
Techniques to prevent procedure-related atheroembolism Vascular 2C . . .
OPCAB technique Cardiac . . . 1A
Remote ischemic preconditioning Cardiac 2B* More research needed for vascular
and low risk cardiac surgery
Minimization of aortic manipulation Cardiac . . . More research needed
MAP >75 Cardiac . . . More research needed
Intraoperative ultrafiltration Cardiac . . . More research needed
Postoperative KDIGO bundle Cardiac 1B* . . .
Low tidal volume ventilation strategy Cardiac 1C . . .
Loop diuretics (for prevention of AKI) Cardiac and vascular . . . 1B
Levosimendan Cardiac . . . 1A
Dopamine Cardiac . . . 1A
A-melanocyte-stimulating hormone Cardiac . . . 1B
Vasopressin for vasoplegic shock (vs norepinephrine) Cardiac . . . More research needed
Natriuretic peptides Cardiac . . . More research needed
Fenoldopam Cardiac . . . More research needed
Mannitol Cardiac and vascular . . . More research needed
AAA indicates abdominal aortic aneurysm (includes thoracoabdominal); ACEI, angiotensin-converting enzyme inhibitor; AKI, acute kidney injury; ARB, angiotensin receptor blocker; CPB,
cardiopulmonary bypass; CVS, cardiac and vascular surgery; IABP, intra-aortic balloon pump; KDIGO, Kidney Disease: Improving Global Outcomes; MAP, mean arterial pressure; OPCAB. off-
pump coronary artery bypass.
*High-risk cardiac surgery patients.
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index >2.2 L/min per m2) after cardiac surgery, vasopressin
was associated with lower incidence of severe AKI (stages 2
and 3) and RRT use, although, again, study limitations prevent
recommendation and further research is needed.154
Nonpharmacological strategies
Perioperative. Again, results in this area are contradictory.
Intravenous contrast before surgery may increase the
incidence of AKI and has led to some recommendations
for delaying surgery 24 to 72 hours after contrast
administration155,156; however, another study disagrees.157
Preoperative placement of an intra-aortic balloon pump may
prevent AKI and reduce the incidence of RRT in high-risk
patients by improving perfusion and reducing endothelial
activation.158,159 Others, however, have suggested that using
an intra-aortic balloon pump as a surrogate to achieve pulsatile
perfusion contributes signiﬁcantly to lowered aortic pressure in
the distal portion of aorta and may impair kidney perfusion.160
Intraoperative. The use of CPB is required for the majority of
cardiac surgical procedures. During CPB, cardiac output is
preserved, but the target blood pressure under such nonpul-
satile conditions is unknown. A large RCT demonstrated that
maintaining a higher level of mean arterial pressure during
normothermic CPB did not reduce the incidence of AKI.161
However, before making any recommendations, further
evidence is required. The impact of off-pump coronary artery
bypass (OPCAB) on renal outcomes has been studied
extensively and remains another point of controversy. OPCAB
exerted a renoprotective effect in patients with normal
preoperative sCr but not in patients with preexisting renal
disease.162 No impact on the incidence of AKI with the 2
competing strategies was seen in some series,163,164 whereas
others found an association of on-pump coronary artery
bypass with higher incidence of AKI.165 A meta-analysis of
trials (n=17 322 patients) suggests a lower risk for AKI but no
difference in the need for RRT in off-pump surgery patients.166
However, a recently published RCT (n=2932 patients) demon-
strated that OPCAB reduced the risk of postoperative AKI in
comparison to on-pump coronary artery bypass grafting, with
no discernable difference in kidney function at 1 year.41
Although data suggest a reduction in AKI in OPCAB, a recent
RCT42 and several meta-analyses167,168 have demonstrated
an increase in long-term, all-cause mortality in OPCAB
compared with on-pump surgery. Consequently, the greater
operative safety and possible prevention of AKI with OPCAB
may come at the expense of long-term survival gains.
Catheter manipulation in the thoracic and abdominal aorta
may lead to renal artery embolization, with aortic cross-
clamping proximal to the renal arteries associated with
ischemia–reperfusion injury, further aggravated by atheroem-
boli secondary to aortic manipulation.169,170 Aortic clamping
above bilateral renal arteries, adjunctive renal artery proce-
dures, and left renal vein division have been found to increase
the incidence of AKI.136 Emboli protection devices may help
preserve renal function and prevent procedure-related
atheroembolism during endovascular renal interventions.171
Transradial coronary angiography avoids catheter manipula-
tion in the descending and abdominal aorta, which, com-
pounded by reduced bleeding, leads to less AKI than
transfemoral angiography.172 Avoidance of aortic manipula-
tion (the “no touch” technique) in OPCAB has been shown to
decrease the risk of postoperative stroke in several studies;
however, its effect on AKI incidence remains controversial,
with some studies demonstrating lower incidence,173,174 but
others failing to do so.175,176
Moderate hypothermic circulatory arrest with antegrade
cerebral perfusion during complex aortic surgery has been
embraced by an increasing number of surgical groups, with data
suggesting that this is not associated with an increased AKI
risk.177 Conversely, hyperthermic perfusion during CPB,
deﬁned as a cumulative time at >37°C, is associated with an
increase in AKI incidence.178 In a study achieving clinical
equipoise through propensity score matching, duration of
hyperthermic perfusion was independently associated with
severity of AKI, with a 51% increase in the incidence for every
10 minutes of hyperthermic perfusion.179 Cold renal perfusion
has been suggested for pararenal abdominal aorta aneurysm
surgery to reduce the incidence of AKI associated with
juxtarenal and thoracoabdominal aortic operations.180–182
Pulsatile perfusion provides surplus mechanical energy
transmission to the vascular endothelium. Its impact on
clinical outcomes has been extensively studied in a variety of
settings; however, the data on renal outcomes are conﬂicting
because of the lack of uniformity in pulsatility delivery.159,183–
185 A retrospective analysis showed pulsatile CPB conferred a
renoprotective effect in higher risk patients undergoing
cardiac surgery.186 However, the contemporary use of
implantable continuous-ﬂow left ventricular assist devices
challenges this concept.187 The improvement in the hemody-
namic environment provided by continuous-ﬂow left ventric-
ular assist devices leads to better renal function in heart
failure patients, implying that the theoretical importance of
pulsatility is superseded by increased cardiac output.187,188
Hemodilution during CPB is an independent risk factor for
AKI in adult cardiac surgery,189 with improved outcomes for
cases in which signiﬁcant hemodilution (hematocrit <24%) is
avoided during CPB.190 Although lower hemoglobin (8.8 versus
13.1 g/dL) preoperatively and on arrival to the intensive care
unit has been associated with persistent AKI after cardiac
surgery,191 transfusion of at least 2 U of packed red blood cells
has also been associated with higher incidence of CVS-AKI.192
In 2 recent RCTs in which patients were randomized to a liberal
(Hg <9.5 g/dL) or restrictive (Hg <7.5 g/dL) transfusion policy
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intraoperatively and postoperatively, there was no difference in
postoperative outcomes including AKI.193,194 In addition,
studies have failed to demonstrate any beneﬁt in the use of
erythropoietin in the prevention of postoperative AKI.109–111
Conventional ultraﬁltration has been used to treat the hemod-
ilutional effects of CPB circuits, but routine adoption does not
seem to be efﬁcacious, with a recent study demonstrating a
higher adjusted risk of AKI.195
As discussed, the effect of RIPC on renal function yields
conﬂicting results.24–26 In high-risk patients undergoing
cardiac surgery, the rate of AKI and the need for RRT have
been found to be signiﬁcantly decreased using RIPC,196
whereas in studies of unselected patients with nonstandard-
ized intraoperative technique, no renal beneﬁt was
observed.25,26 Results of recent meta-analyses have failed
to demonstrate the efﬁcacy of RIPC in reducing the incidence
of AKI or the need for RRT.197–200 Importantly, these meta-
analyses included studies involving low-risk patients and
studies that used propofol. In a subgroup of studies in which
propofol was not used, a reduction in AKI was demonstrated,
suggesting a possible interaction of propofol with the
protective effects of RIPC.200 Data for vascular surgery
patients are also conﬂicting and limited to 4 small RCTs in
patients undergoing open or endovascular abdominal aortic
aneurysm repair, the majority of whom showed no beneﬁt
with RIPC in preventing AKI.201–204
Postoperative. Implementation of a “KDIGO bundle of
care”—consisting of avoidance of nephrotoxic agents, dis-
continuation of angiotensin-converting enzyme inhibitors and
angiotensin receptor blockers for the ﬁrst 48 hours after
surgery, close monitoring of sCr and UO, avoidance of
hyperglycemia for the ﬁrst 72 hours after surgery, consider-
ation of alternatives to radiocontrast agents, and close
hemodynamic monitoring using a prespeciﬁed algorithm—
prevented CVS-AKI in high-risk patients deﬁned as biomarker
positive.67,93 A lower rate of CS-AKI has been shown in
patients ventilated with low (<10 mL/kg) tidal volume
compared with traditional (10–12 mL/kg) or high (>12 mL/
kg) tidal volumes after cardiac surgery.205
Management of CVS-AKI
Workup and monitoring
Recommendations:
1. The choice of diagnostic tests and monitoring for patients
with CVS-AKI is determined by the presence and the
degree of kidney and/or cardiorespiratory dysfunction (not
graded).
2. The diagnostic approach depends on the etiology of organ
dysfunction and the expected short- and long-term patient
outcomes (not graded).
3. A kidney-speciﬁc and stepwise diagnostic approach for
patients with CVS-AKI and cardiorespiratory dysfunction
may be helpful (not graded).
Rationale: Effective interventions to reverse the conse-
quences of AKI remain elusive, with efforts focusing on
primary prevention. Nevertheless, management of patients
who sustain AKI is of vital importance, both to reduce the
immediate impact of AKI and to avoid further episodes of AKI
and avert the progression of AKI to acute kidney disease or
CKD. Organ functional changes are dynamic, and, as such,
frequent assessments are required to establish the trajectory
that will inﬂuence the nature and urgency of interventions.
Such assessments should guide preemptive therapies to
prevent or manage complications that are anticipated in the
setting of AKI. Because the impact of CVS-AKI on both short-
and long-term outcomes of patients is signiﬁcant, reaching
appropriate diagnoses to provide etiology-speciﬁc individual-
ized preventive and/or therapeutic measures is critical. The
diagnostic tests and monitoring strategies available are
manifold (Table 2) and should be determined by the level of
kidney or cardiorespiratory dysfunction present (Figure 4A
and 4B).
If no evidence shows cardiopulmonary failure, it is
essential to try to identify the etiology of the AKI. Following
evaluation of cardiorespiratory function and intravascular
volume status, urine analysis and medication review are
initial steps in assessing such patients. The use of stress or
injury biomarkers of AKI may potentially allow more accurate
prognostication of AKI because they have been shown to
correlate with long-term outcomes.206,207 When AKI persists
for >48 to 72 hours, nephrology consultation to evaluate
other potential causes of AKI and, potentially, disease-
speciﬁc management may be helpful. For patients who
require RRT, close monitoring of metabolic milieu and
hemodynamic/volume status is critical. Once discharged,
clinicians should follow patients who recovered from CVS-
AKI for the development of CKD or other post-AKI
complications.2
Pharmacological and nonpharmacological support
Recommendations:
1. The management goals for the CVS patient who has
sustained AKI include preventing the progression of AKI,
promoting renal recovery precluding subsequent episodes
of AKI, and treating the acute and chronic consequences
of AKI (not graded).
2. We recommend not using natriuretic peptide, fenoldopam,
diuretics, dopamine, or mannitol for the treatment of CVS-
AKI (grade 1C).
3. The decision to start RRT should be individualized with
considerationof theclinical context andnot bebasedsolely on
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Table 2. Suggested Diagnostic Tests and Monitoring Strategies for CVS-AKI
Category Test Patients Advantage Disadvantage
Cardiovascular
function
Basic hemodynamic monitoring (MAP,
cardiac filling pressure, and its
trends, SpO2, HR, RR, temperature)
All patients Identification of patients with
need for advanced
monitoring
Ability to evaluate the trends
Low resolution
Questionable relationship
with volume deficiency
Advanced hemodynamic monitoring
(thermodilution, transpulmonary
indicator dilution, arterial-pressure
waveform-derived, esophageal or
suprasternal Doppler, echocardiography,
partial CO2 rebreathing, bioimpedance,
and bioreactance)
Progressive or severe AKI
Hemodynamic instability
Accuracy
High resolution
Invasive
Limited evidence for effect
on outcomes
Assist device–related information Patients who need
cardiorespiratory support
Readily available
Informative
Requires expertise to
interpret
Lactate Progressive or severe AKI
Hemodynamic instability
Indicator of tissue O2
delivery
Clearance guides therapy
Lacks specificity (eg,
epinephrine-induced
increase in lactate)
SVO2 or ScVO2 Progressive or severe AKI
Hemodynamic instability
Balance of tissue O2 delivery
and consumption
Sensitivity can be reduced
with shunting and when
O2 consumption is low
Pulmonary
function
Blood gas Cardiorespiratory
dysfunction
Accurate measure of
oxygenation and ventilation
Limited information
concerning cardiac
performance
Lung US Cardiorespiratory
dysfunction
Noninvasive
Sensitive and specific
Interrater variability
Lung imaging Cardiorespiratory
dysfunction
Simple, uniformly available X-ray exposure; Specificity
can be limited
Lung compliance Patients on MV Easy to perform May lack specificity
Kidney function sCr All patients with CVS-AKI Available
Informative (diagnosis and
prediction)
Late and insensitive
biomarker of kidney
dysfunction
Urine sediments Kidney dysfunction High specificity Low sensitivity
Urine electrolytes Kidney dysfunction Available
Confirmatory
Limited sensitivity and
specificity, Confounded
by diuretics
Injury/stress biomarkers CVS-AKI
(AKI risk and stage I)
Informative (diagnosis,
prognosis)
Less delayed
Limited availability in
some areas
Kidney US Suspicion of obstruction Highly sensitive and specific Interrater variability
Kidney Doppler US Progressive kidney
dysfunction
Noninvasive Lack of specificity of
resistive index
Limited images in ICU
Urine eosinophils Progressive kidney
dysfunction and clinical
suspicion of AIN/
atheroembolic disease
Reasonable specificity Low sensitivity
Kidney biopsy Progressive kidney disease
with unknown etiology
Informative (diagnosis,
prognosis)
Not done in usual clinical
practice
Miscellaneous Chemistry panel All patients with CVS-AKI Available
Informative (eg, to assess
AKI complications)
Glucose monitoring All CVS-AKI patients Allows appropriate glucose
management
Continued
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renal function or stage ofAKI. Once the decision to initiate RRT
has been made, it should be started promptly (not graded).
4. We recommend the use of continuous therapies in patients
with hemodynamic instability and in situations in which
shifts in ﬂuid balance are poorly tolerated (grade 1B).
Rationale: For those patients with CVS-AKI who present
with cardiorespiratory failure, the diagnostic approach needs
to focus ﬁrst on addressing cardiorespiratory dysfunction.
Among patients who have signiﬁcant baseline or acute
cardiorespiratory failure or who require substantial support
for heart and lung function, the intensity of hemodynamic and
intravascular volume status monitoring should be esca-
lated.208 The hemodynamic management of cardiac surgery
patients with renal dysfunction should focus on:
1. Improvement of right and left ventricular function
2. Maintenance of MAP and sinus rhythm
3. Optimization of preload
4. Management of right ventricle afterload (pulmonary vas-
cular resistance)
5. Optimization of mechanical ventilation
Pharmacological cardiac support. A multipharmacological
approach is frequently necessary. Catecholamines are often
required to improve ventricular function, acting through a
direct inotropic effect but also by improving myocardial
perfusion and recruitment of unstressed venous preload.
Phosphodiesterase type III inhibitors (milrinone and enoxi-
mone), calcium sensitizers (levosimendan), and pulmonary
vasodilators (inhaled nitric oxide, inhaled prostacyclin, and
inhaled milrinone) can improve cardiac performance while
reducing afterload on both right and left ventricles. Because
the determinant for renal perfusion is the arterial and venous
blood pressure, both left ventricle dysfunction and increased
central venous pressure are associated with decreased renal
perfusion and increased renal afterload contributing to CS-
AKI.209 As noted, increased renal venous pressure also causes
an increase in the renal subcapsular pressure, thereby reducing
glomerular ﬁltration.210 The use of dynamic measures based on
heart–lung interactions to predict ﬂuid responsiveness, such as
pulse pressure or stroke volume variation, has been shown to
improve outcomes including renal function in both cardiac and
noncardiac settings.211 Fluid overload is particularly problem-
atic following cardiac surgery because of the frequent co-
occurrence of low cardiac output and postcardiotomy ventric-
ular impaired relaxation. Following the acute phase, slow and
controlled volume unloading, through the use of diuretics and/
or continuous RRT, is frequently necessary.
Pharmacological kidney support. Pharmacological man-
agement of CVS-AKI remains challenging, with no speciﬁc
approaches available currently. Many drugs including dopa-
mine, loop diuretics, mannitol, and natriuretic peptides have
been investigated as primary renal therapy. Although
Table 2. Continued
Category Test Patients Advantage Disadvantage
Myoglobin and sarcoplasmic
proteins (eg, creatine kinase,
aldolase, LDH, ALT, and AST)
Progressive AKI with clinical
suspicion
Informative (rhabdomyolysis
diagnosis)
Complement Progressive AKI with clinical
suspicion of
immunologically mediated
renal disease (eg,
atheroembolic disease,
infection, I/R)
Confirmatory Low sensitivity
ESR/CRP Progressive AKI with clinical
suspicion (eg,
Atheroembolic disease,
infection, I/R)
Confirmatory
Peripheral blood smear and
hemolysis panel
Progressive AKI with clinical
suspicion of hemolysis
associated AKI (eg, HUS/
TTP, DIC)
Confirmatory
Inflammatory biomarkers Vasodilatory shock Predictor of outcome Limited availability; no
standardization
AIN indicates acute interstitial nephritits; AKI, acute kidney injury; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; CVS, cardiac and vascular
surgery; DIC, disseminated intravascular coagulation; ESR, erythrocyte sedimentation rate; HR, heart rate; HUS, hemolytic uremic syndrome; ICU, intensive care unit; I/R, ischemia/
reperfusion; LDH, lactate dehydrogenase; MAP, mean arterial pressure; MV, mechanical ventilation; RR, respiratory rate; sCr, serum creatinine; SpO2, peripheral oxygen saturation; ScVO2,
central venous oxygen saturation; SVO2, systemic venous oxygen saturation; TTP, thrombotic thrombocytopenic purpura; US, ultrasound.
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associated with increased UO, none are routinely used
because of limited and conﬂicting data and, in some cases,
evidence of harm.140,145,212 RCTs with natriuretic peptides
have shown inconsistent effects for renal end points. Meta-
analyses demonstrated that atrial natriuretic peptide in high
doses was associated with a trend toward increased mortality
and more adverse events in patients undergoing cardiac
surgery.144 Although there was a reduced need for RRT (with
the associated problems using RRT as an end point) with low-
dose atrial natriuretic peptide in patients undergoing CVS,
there was no difference in mortality. The majority of studies
on atrial natriuretic peptide are underpowered and of low or
Figure 4. A, Cardiorespiratory-speciﬁc diagnostic approach. This diagnostic approach may be applied to a
patient who has a cardiorespiratory cause of acute kidney injury (AKI). The level of intervention is governed
by the degree and chronicity of cardiorespiratory dysfunction. Source: ADQI (Acute Disease Quality
Initiative) 20th consensus meeting (http://www.adqi.org). Used with permission. B, Kidney-speciﬁc
diagnostic approach. This diagnostic approach may be applied to a patient who has a renal-speciﬁc cause of
AKI. The level of intervention is governed by the degree and duration of renal dysfunction. This is particularly
relevant in the post–intensive care unit phase, in which a patient with persistent AKI (>2 or 3 days) or acute
kidney disease should be monitored and followed up. BNP indicates brain natriuretic peptide; CI, cardiac
index; CKD, chronic kidney disease; CO, cardiac output; CVP, central venous pressure; CXR, chest x-ray;
EVLW, extravascular lung water; HR, heart rate; MAP, mean arterial pressure; RR, respiratory rate; ScVO2,
central venous oxygen saturation; SpO2, peripheral oxygen saturation; SVV, stroke volume variation; US,
ultrasound.
DOI: 10.1161/JAHA.118.008834 Journal of the American Heart Association 14
Cardiac and Vascular Surgery–Associated AKI Nadim et al
S
P
E
C
IA
L
R
E
P
O
R
T
D
ow
nloaded from
 http://ahajournals.org by on October 25, 2019
moderate quality; therefore, atrial natriuretic peptide is not
currently recommended for treatment of AKI.213 Although
meta-analyses have suggested a decrease in RRT in patients
with CS-AKI who were treated with fenoldopam, a multicenter,
randomized, double-blind, placebo-controlled, parallel-group
study of patients with CS-AKI (n=667) was stopped for futility
after an interim analysis. Fenoldopam infusion did not reduce
30-day mortality or the need for RRT but was associated with
an increased rate of hypotension compared with placebo.140
Renal replacement therapy. In patients undergoing cardiac
surgery, perioperative ﬂuid overload has been associated with
worse outcomes and is a primary risk factor for multiorgan
failure, including AKI.214–216 Fluid balance can be achieved
with pharmacological agents; however, in some cases, RRT
should be considered to correct ﬂuid accumulation, even in
nonoliguric patients if the daily ﬂuid balance cannot be
maintained or is negative with the use of diuretics, to avoid
the negative effects of prolonged ﬂuid overload in critically ill
patients (Figure 5).217–219
The optimal timing of RRT initiation remains a topic of
much debate. Theoretically, initiation of RRT before the onset
of severe AKI could improve survival and promote earlier
recovery of kidney function by mitigating injury from acidemia,
uremia, ﬂuid overload, and systemic inﬂammation.220
However, early initiation may put patients at risk associated
with RRT when a conservative approach could be used.
Meta-analyses examining the timing of initiation of RRT221–224
have suggested that earlier initiation of RRT in critically ill
patients with AKI may have a beneﬁcial impact on survival. A
Figure 5. Fluid management strategies in critical illness: the place of mechanical ﬂuid removal.
Once life-threatening hypovolemia has been corrected (savage resuscitation), ﬂuid overload (FO)
needs to be avoided. Early mechanical ﬂuid removal should be considered if speciﬁc indications
exist. Note, the existence of an extracorporeal circuit for extracorporeal membrane oxygenation
(ECMO) greatly reduces any added risk for renal replacement therapy (RRT), assuming this circuit is
used rather than a separate line for RRT. However, some patients will respond well to diuretics, and
thus an ECMO circuit in place is only a relative indication for early RRT initiation and only when ﬂuid
or solute management dictates. During therapy, hemodynamic and intravascular volume status
should be monitored and ﬂuid removal rate and ﬂuid balance targets reassessed regularly, aiming
for clinical stability and tolerance of ﬂuid removal. Within this pathway, RRT should be considered at
any point if additional solute clearance is necessary. FB indicates ﬂuid balance; UF, ultraﬁltration.
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few small RCTs were included, as well as numerous obser-
vational and cohort studies of various qualities with high
heterogeneity. Although AKI stage correlates with hospital
mortality, many patients with stage 3 AKI will show sponta-
neous recovery without RRT. In addition, some patients may
have urgent indications for RRT (eg, ﬂuid overload not
responding to diuretics) without meeting severe AKI criteria.
The decision to start RRT should be individualized.219
Recently, 2 large RCTs in critically ill patients compared
“early” versus “late” RRT.225,226 In the ELAIN (Early vs Late
Initiation of Renal Replacement Therapy In Critically Ill Patients
With Acute Kidney Injury) trial (n=231), patients with AKI stage
2 and serum NGAL >150 ng/mL were randomized to early
(RRT within 8 hours of AKI stage 2) or late (RRT within
12 hours of reaching AKI stage 3) RRT.225 Approximately half
of the patients were cardiac surgery patients (47%). Patients in
the early RRT group had 25% lower mortality compared with
those in the late arm. Only 10% of patients in the late group
did not receive RRT. In the AKIKI (Artiﬁcial Kidney Initiation in
Kidney Injury) trial (n=620), patients were randomized to early
treatment, deﬁned as RRT within 6 hours of reaching AKI
stage 3, or late treatment, deﬁned as RRT initiation when
“absolute” indications were fulﬁlled.226 Mortality (50%) was
not signiﬁcantly different between the 2 groups, but approx-
imately half of the patients randomized to late treatment did
not receive RRT. Patients in the late treatment group who
started RRT had higher mortality (62%) compared with
patients in the early RRT group (48.5%). Forty percent of the
patients were excluded on the basis of having emergent
indications, already receiving RRT, or having indications for
initiation of RRT for >5 hours. Clearly, these 2 trials do not
deﬁnitively identify which patients are likely to beneﬁt most
from early initiation of RRT.
Studies of dialysis modality (continuous versus intermit-
tent) have failed to demonstrate a consistent beneﬁt of
one technique over another.227 However, continuous RRT is
Table 3. Knowledge Gaps and Future Research Directions in CVS-AKI
Knowledge Gap Future Research Directions
Risk assessment 1 Defining the association of KDIGO stage 1 AKI by urine output and sCr with outcomes in the CVS settings
2 Investigation of acute kidney stress are warranted to better characterize the incidence and outcomes of those with
elevations in injury and damage biomarkers before changes in sCr and urine output
3 Development of iterative risk-prediction models that allow reevaluation of risk in the pre-, peri-, and postoperative periods.
In this context, we recommend evaluation of the incremental value of real-time estimated GFR assessment and renal
injury/stress biomarkers as part of a risk stratification strategy
4 Feasibility studies to assess renal reserve in the preoperative period for unrecognized renal susceptibility in selected
group of patients
Risk stratification 1 Development and validation of current and emerging biomarkers of AKI diagnosis, recovery, progression to CKD
2 Research and development of noninvasive, inexpensive, and highly accurate devices for kidney function, hemodynamic,
and volume status monitoring (eg, real-time GFR monitoring devices, kidney perfusion, and intracapsular pressure monitors,
etc)
3 Design and investigation of the impact of the biomarker or technology-guided protocols in the prevention or treatment of
CVS-AKI
Prevention of CVS-AKI 1 Development of biomarker or diagnostic tool-guided protocols to prevent the progression of CVS-AKI or facilitate kidney
function recovery
2 Investigation and validation of biomarkers and diagnostic tools with more resolution or ability to identify intravascular
volume deficiency, microcirculation deficits, and kidney-related variables and outcomes (eg, severity and location of injury,
real-time kidney function measures, biomarkers of kidney recovery, fibrosis or de novo or progression of CKD or
need for RRT)
3 Development of noninvasive, inexpensive, and highly accurate devices for kidney function, hemodynamic, and
volume status monitoring (eg, real-time GFR monitoring devices, kidney perfusion, and intracapsular pressure monitors, etc)
Management of CVS-AKI 1 Development of studies to verify if specific management approaches currently showed as effective in CVS-AKI primary
prevention are also useful for secondary prevention
2 Improvement of definition and monitoring of fluid overload in order to better understand its relationship and
management strategies in CVS-AKI patients
3 Development of large randomized trial on ANP for the prevention and treatment of AKI
4 Evaluation of the role of stem cells in treatment of AKI
AKI indicates acute kidney injury; ANP, atrial natriuretic peptide; CKD, chronic kidney disease; CVS, cardiac and vascular surgery; GFR, glomerular ﬁltration rate; KDIGO, Kidney Disease
Improving Global Outcome; RRT, renal replacement therapy; sCr, serum creatinine.
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recommended for patients with hemodynamic instability that
exceeds the ability to manage patients safely with intermittent
hemodialysis.213,219,228 In addition, ﬂuid removal is generally
easier and associated with less hemodynamic instability when
using continuous RRT.229,230 It is possible that the operational
characteristics of RRT might inﬂuence renal and patient
recovery. Several observational studies have suggested that
intermittent hemodialysis compared with continuous RRT is
associated with less renal recovery and a higher risk of long-
term dialysis dependency.231,232
Stem cells. Use of mesenchymal stem cells, which are
nonhematopoietic precursor cells derived from human bone
marrow, is currently under investigation (2 trials completed
and being analyzed) for the treatment of CS-AKI.233,234 The
role of mesenchymal stem cells in AKI treatment might
depend on the secretion of promitotic, antiapoptotic, anti-
inﬂammatory, and immunomodulatory factors.235
Knowledge Gaps and Future Research
Currently, there is a paucity of data regarding diagnosis,
prevention, and treatment, especially in patients undergoing
vascular surgery. Consequently, it is imperative to develop
research questions to address these issues (Table 3). For
many of the pharmacological agents available for the
prevention or management of AKI in this setting, larger
RCTs will be needed to determine efﬁcacy in different
clinical scenarios. It is important to establish the utility of
new biomarkers, not only for the early diagnosis and staging
of AKI but also for the implementation of preventive
measures.
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Data S1. 
 
ADQI METHODOLOGY 
Our consensus process relied on evidence where available and, in the absence of evidence, 
consensus expert needed opinion where possible as described previously. Our methods comprise (i) 
a systematic search for evidence with review and evaluation of the available literature; (ii) the 
establishment of clinical and physiological outcomes and also measures to be used for comparison of 
different treatments; (iii) the description of current practice and the rationale for the use of current 
techniques; and (iv) the analysis of areas in which evidence is lacking and future research is required 
to obtain new information. The topics chosen for each conference are selected on the basis of the 
following criteria: (i) prevalence of the clinical problem; (ii) estimate of variation in clinical practice; (iii) 
potential influence on outcome; (iv) potential for development of evidence-based guidelines; and (v) 
availability of scientific evidence. 
The activities of ADQI conferences are conducted in three stages: (1) pre-conference, (2) conference, 
and (3) post- conference. Prior to the conference, we identified four topics for discussion pertaining to 
Cardiac and Vascular associated acute kidney injury (AKI). Conference participants were divided into 
four working groups, (i. Pathophysiology; ii. Diagnosis and risk assessment; iii. Prevention; and iv. 
Workup and Management) and tasked with the development of practice recommendations as well as 
research recommendations where knowledge gaps were recognized. Panelists were assigned to one 
of the work groups, with one member serving as the group facilitators. Conference directors circulate 
between the breakout groups and also serve as facilitators and moderators for plenary sessions.  
Summary statements were developed through a series of breakout sessions where individual work 
group members were required to identify key issues for which recommendations were needed and to 
classify current state of consensus and identify supporting evidence for each issue. Workgroup 
members were then required to present their findings to the entire group, revising each statement as 
needed until a final version was agreed upon. The responsibility for presenting the findings of the work 
group to the rest of the participants was shared by each member on a rotating basis. Group facilitators 
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revised work group findings as needed after each plenary session. Directives for future research were 
achieved by asking the participants to: a) identify deficiencies in the literature, b) determine if more 
evidence is necessary, and c) if so, and articulate general research questions. When possible, 
pertinent study design issues are also considered. Special observers had a scheduled rotation through 
each of the four workgroups to provide input. In each breakout session, the workgroups refined the 
key questions, identified the supporting evidence, and generated recommendations and/or directions 
for future research as appropriate. Summary statements were developed through these series of 
alternating breakout and plenary sessions and were further refined until final versions were agreed 
upon. A writing committee assembled the individual reports from the work groups. Each report was 
edited to conform to a uniform style and for length. The final reports were mailed to each participant 
for comment and revision. Once final reports were completed, the writing committee summarized the 
individual reports into a final conference document that is submitted for publication. 
For each group topic studies were identified via MEDLINE, PubMed search, bibliographies of review 
articles and participants' files. Searches were limited to English language articles. We excluded studies 
on pediatric population. Each group identified a list of key questions and reviews of the literature were 
performed in a systematic manner prior to the meeting, as directed by the Workgroup chairs. Although 
nonrandomized studies were also reviewed, the majority of the Workgroup resources were devoted to 
review of randomized controlled trials (RCTs), as these were deemed to be most likely to provide data 
to support level 1 recommendations with very high- or high-quality (A or B) evidence. Exceptions were 
made by incorporating the best available evidence and expert opinion for topics with sparse evidence.  
Through consensus of opinion, the available literature was distilled and presented iteratively to the 
conference participants with the final outputs assessed and aggregated in a plenary session who 
formally approved the consensus recommendations. The quality of the overall evidence and the 
strength of recommendations were graded using the Grading of Recommendations Assessment, 
Development and Evaluation system. Evidence was classified according to levels per EBM 
methodology. 
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